[go: up one dir, main page]

BR9914116A - Composições e métodos para imunoterapia especìfica de wt1 - Google Patents

Composições e métodos para imunoterapia especìfica de wt1

Info

Publication number
BR9914116A
BR9914116A BR9914116-7A BR9914116A BR9914116A BR 9914116 A BR9914116 A BR 9914116A BR 9914116 A BR9914116 A BR 9914116A BR 9914116 A BR9914116 A BR 9914116A
Authority
BR
Brazil
Prior art keywords
compositions
methods
polypeptide
specific immunotherapy
cell
Prior art date
Application number
BR9914116-7A
Other languages
English (en)
Inventor
Alexander Gaiger
Martin Cheever
Original Assignee
Corixa Corp
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corp, Alexander Gaiger filed Critical Corixa Corp
Publication of BR9914116A publication Critical patent/BR9914116A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA IMUNOTERAPIA ESPECìFICA DE WT1". Descreve-se composições e métodos para a terapia de doenças malignas, como leucemia e câncer. As composições compreendem um ou mais entre um polinucleotideo de WTI, um polipeptídeo de WT1, uma célula apresentadora de antígeno que apresenta um polipeptídeo de WT1, um anticorpo que liga-se especificamente a um polipeptídeo de WT1; ou uma célula T que reage especificamente com um polipeptídeo de WT1. Essas composições podem ser usadas, por exemplo, para a prevenção e tratamento de doenças metastáticas.
BR9914116-7A 1998-09-30 1999-09-30 Composições e métodos para imunoterapia especìfica de wt1 BR9914116A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
BR9914116A true BR9914116A (pt) 2002-01-15

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914116-7A BR9914116A (pt) 1998-09-30 1999-09-30 Composições e métodos para imunoterapia especìfica de wt1

Country Status (25)

Country Link
EP (1) EP1117687B1 (pt)
JP (3) JP4243792B2 (pt)
KR (1) KR100752065B1 (pt)
CN (1) CN100486995C (pt)
AR (1) AR021849A1 (pt)
AT (1) ATE399179T1 (pt)
AU (1) AU6407899A (pt)
BR (1) BR9914116A (pt)
CA (1) CA2349442C (pt)
CZ (1) CZ20011144A3 (pt)
DE (1) DE69938970D1 (pt)
ES (1) ES2310052T3 (pt)
HK (1) HK1039782B (pt)
HU (1) HUP0103598A3 (pt)
IL (2) IL142216A0 (pt)
MX (1) MXPA01003344A (pt)
MY (1) MY139226A (pt)
NO (1) NO325839B1 (pt)
NZ (1) NZ510600A (pt)
PL (1) PL201881B1 (pt)
RU (1) RU2237674C2 (pt)
SA (1) SA00200872B1 (pt)
TR (1) TR200101482T2 (pt)
TW (1) TWI285648B (pt)
WO (1) WO2000018795A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
HK1038929B (zh) 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
CN1281625C (zh) * 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
US20060165708A1 (en) * 2001-06-29 2006-07-27 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
EP1447091A4 (en) * 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
AU2003264514A1 (en) 2002-09-20 2004-04-08 Chugai Seiyaku Kabushiki Kaisha Wt1 substitution peptides
KR101399678B1 (ko) 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
ES2378156T3 (es) 2003-06-27 2012-04-09 International Institute Of Cancer Immunology, Inc. Método para seleccionar pacientes adecuados para vacuna de WT1
PT2071028E (pt) 2003-11-05 2012-04-10 Int Inst Cancer Immunology Inc Péptido antigénico de ligação a hla-dr derivado de wt1
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
PL1961761T3 (pl) * 2005-11-30 2011-04-29 Int Inst Cancer Immunology Inc Oligomeryczne amidoaminy lub amidokwaty do kompozycji do obróbki tkanin lub włosów
EP2518149B1 (en) * 2006-02-22 2015-12-16 International Institute of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
KR101493773B1 (ko) * 2006-10-17 2015-03-03 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
WO2008081701A1 (ja) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
RU2009135802A (ru) 2007-02-27 2011-04-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) Способ активации хелперных т-клеток и композиция для применения в данном способе
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
KR101900639B1 (ko) 2007-03-05 2018-09-19 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
IN2011KN04700A (pt) * 2009-05-19 2015-07-10 Univ Miami
KR102079480B1 (ko) 2010-10-05 2020-02-19 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
US9074000B2 (en) 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
JP6066909B2 (ja) 2011-06-28 2017-01-25 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
WO2014142102A1 (ja) 2013-03-12 2014-09-18 大日本住友製薬株式会社 液体水性組成物
DK2982681T3 (en) * 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
EP2998740B1 (en) * 2013-05-13 2023-07-05 International Institute of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
KR102797324B1 (ko) * 2014-12-11 2025-04-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
RU2743381C2 (ru) * 2015-09-10 2021-02-17 Мемориал Слоан-Кеттеринг Кэнсер Сентер Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии
CA3005896C (en) * 2015-11-20 2025-09-23 Memorial Sloan Kettering Cancer Center METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY MEANS OF THE COMBINATION OF A WT1 PEPTIDE AND A CHECKPOINT INHIBITOR
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
CN111533797A (zh) * 2017-04-10 2020-08-14 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
JP6933778B2 (ja) 2017-12-21 2021-09-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ−ａ２／ｗｔ１に結合する抗体
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
EP4151227A4 (en) 2020-05-12 2025-01-15 Sumitomo Pharma Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
EP4385519A4 (en) 2021-08-12 2025-08-06 Int Inst Cancer Immunology Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER
EP4410304A4 (en) * 2021-09-24 2025-08-27 Cha Vaccine Res Institute Co Ltd CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原

Also Published As

Publication number Publication date
HK1039782A1 (en) 2002-05-10
KR100752065B1 (ko) 2007-08-28
CZ20011144A3 (cs) 2002-06-12
AR021849A1 (es) 2002-08-07
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
CA2349442A1 (en) 2000-04-06
MXPA01003344A (es) 2004-04-21
JP4243792B2 (ja) 2009-03-25
NO20011613L (no) 2001-05-29
JP4235984B2 (ja) 2009-03-11
SA00200872B1 (ar) 2007-01-30
CA2349442C (en) 2012-12-04
PL348595A1 (en) 2002-06-03
AU6407899A (en) 2000-04-17
CN100486995C (zh) 2009-05-13
TW200606176A (en) 2006-02-16
DE69938970D1 (de) 2008-08-07
CN1336935A (zh) 2002-02-20
EP1117687A2 (en) 2001-07-25
IL142216A0 (en) 2002-03-10
JP2008069172A (ja) 2008-03-27
HUP0103598A2 (hu) 2002-01-28
TR200101482T2 (tr) 2002-01-21
WO2000018795A2 (en) 2000-04-06
TWI285648B (en) 2007-08-21
RU2237674C2 (ru) 2004-10-10
WO2000018795A9 (en) 2000-08-31
EP1117687B1 (en) 2008-06-25
JP2007001984A (ja) 2007-01-11
KR20010085861A (ko) 2001-09-07
ATE399179T1 (de) 2008-07-15
NO20011613D0 (no) 2001-03-29
HUP0103598A3 (en) 2005-11-28
WO2000018795A3 (en) 2000-10-26
NO325839B1 (no) 2008-07-28
JP2002525099A (ja) 2002-08-13
IL142216A (en) 2009-06-15
PL201881B1 (pl) 2009-05-29
NZ510600A (en) 2003-12-19
MY139226A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
ATE402189T1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0113235A (pt) Composições e métodos para a terapia e a diagnose de malignidades associadas com her-2/neu
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
EP1575509A4 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
BG101024A (bg) Моноклонално антитяло срещу сd44v6
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
EP0552296A4 (en) Mouse monoclonal antibodies
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
DE59504707D1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
DK0454782T3 (da) Cancer-beslægtet haptaglobin (Hpr.)
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
SE8304111D0 (sv) Amino derivatives of benzylidene-pyrrolo(2,1-b)-quinazolines and benzylidene-pyrido(2,1-b)quinazolines

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII E IX), 11, 13 E 24 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.